Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during the specified class period [1]. Group 1: Allegations - The complaint alleges that 3D Systems understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [1]. - It is also claimed that updated milestone criteria in the partnership with United Therapeutics Corporation would negatively affect the revenue from the company's regenerative medicine program [1]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as August 13, 2024, to May 12, 2025 [1]. - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [3].

Core Insights - 3D Systems has achieved FDA approval for a 3D bioprinting solution for the regenerative repair of peripheral nerve damage, in collaboration with TISSIUM [1][4] - The newly developed device, COAPTIUM® CONNECT with TISSIUM Light, is a bioabsorbable, atraumatic, and sutureless solution for nerve repair, marking a significant milestone in the industry [1][4] - The global 3D bioprinting market is projected to grow from $1.3 billion in 2024 to $2.4 billion by 2029, indicating strong growth potential for the sector [3] Company Developments - 3D Systems has been a leader in bioprinting for nearly a decade, focusing on developing technologies for regenerative medicine and personalized healthcare [2][3] - The company has collaborated with United Therapeutics Corporation since 2017 to create an unlimited supply of human lungs for transplantation, showcasing its commitment to advancing medical solutions [2][3] - 3D Systems has produced over two million implants and instruments for more than 100 CE-marked and FDA-cleared devices, demonstrating its extensive experience in the medical device sector [3] Industry Impact - The collaboration with TISSIUM sets a new standard for high-resolution elastomeric 3D-printed medical implants, enhancing the capabilities of bioprinting technologies [4] - 3D Systems' innovations in bioprinting are expected to transform patient care by enabling the fabrication of living tissues and developing new therapeutics [5] - The advancements in 3D bioprinting are anticipated to accelerate the adoption of additive manufacturing in the medical field, contributing to improved healthcare delivery [4][5]

Core Viewpoint - 3D Systems has successfully completed strategic transactions to refinance its outstanding convertible notes and repurchase shares, enhancing its capital structure and financial flexibility [1][4]. Group 1: Financial Transactions - The company repurchased approximately 8 million shares of its common stock, representing about 6% of its outstanding shares as of May 2, 2025 [1][7]. - The refinancing involved retiring approximately $88 million of debt, which is 41% of the prior balance, at a significant discount to par [7]. - The company issued $92 million in new Convertible Senior Secured Notes due in 2030, with an interest rate of 5.875% per annum [2][7]. Group 2: Financial Impact - The repurchase of existing notes at a discount is expected to result in a gain of approximately $10 million in the second quarter financial statements [3]. - The transactions are anticipated to reduce overall outstanding debt and extend the maturity profile, providing enhanced financial flexibility [4][7]. Group 3: Management Commentary - Dr. Jeffrey Graves, president and CEO, emphasized that these transactions are a significant step in strengthening the company's capital structure and managing potential dilution through share repurchase [4]. - The company has reduced its total debt by over 72% since 2021 through opportunistic transactions [4]. Group 4: Future Outlook - The company maintains strong cash reserves to support ongoing restructuring efforts and key growth initiatives [7]. - The new notes will mature on June 15, 2030, unless converted or repurchased earlier, reflecting a strategic move to manage debt maturity [2][7].

Core Viewpoint - A class action securities lawsuit has been filed against 3D Systems Corporation, alleging securities fraud that affected investors between August 13, 2024, and May 12, 2025 [1][2]. Summary by Sections Class Action Details - The lawsuit claims that 3D Systems Corporation made false statements regarding the impact of reduced customer spending and overstated its resilience in difficult market conditions [2]. - It is also alleged that changes in the partnership with United Therapeutics Corporation would adversely affect the revenue from the Company's regenerative medicine program [2]. Next Steps for Investors - Investors who suffered losses during the specified period have until August 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Group 1 - The Schall Law Firm has initiated a class action lawsuit against 3D Systems Corporation for violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit pertains to investors who purchased 3D Systems securities between August 13, 2024, and May 13, 2025 [2] - The complaint alleges that 3D Systems made false and misleading statements regarding the impact of weakening customer spending and the performance of its Regenerative Medicine Program [4] Group 2 - Investors are encouraged to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3][5] - The class in this case has not yet been certified, meaning that potential class members are not yet represented by an attorney [3] - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [5]

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation for alleged misleading statements and failure to disclose critical information regarding its business performance during the specified Class Period from August 13, 2024, to May 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [5]. - It is alleged that updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [5]. - The lawsuit asserts that the public statements made by 3D Systems were materially false and misleading, leading to investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased 3D Systems securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 12, 2025, to represent other class members in the litigation [3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]. - The firm emphasizes the importance of selecting qualified legal counsel with proven success in securities litigation [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during a specified class period [1][3]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from August 13, 2024, to May 12, 2025 [3]. - Allegations include that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [3]. - Additionally, the updated milestone criteria in the partnership with United Therapeutics Corporation are claimed to negatively impact the company's regenerative medicine program revenue [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [5].

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][8]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [4]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on 3D printing organs for transplantation [4][5]. Financial Performance - In March 2025, 3D Systems projected revenue for 2025 to be between $420 million and $435 million, indicating flat to modest growth, with a non-GAAP Gross Profit Margin of 37% to 39% and non-GAAP Operating Expense of $200 million to $220 million [7]. - The company reported a Q4 2024 non-GAAP earnings-per-share of -$0.19, missing estimates, and a sales revenue of $111 million, down 3.4% year-over-year [9]. - For full-year 2024, sales were reported at $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [9]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [10]. Market Reaction - Following the announcement of disappointing financial results, 3D Systems' stock price fell significantly, dropping 20.96% to $2.15 per share on March 27, 2025, and further declining 26.6% to $1.87 per share on May 13, 2025 [9][11]. Allegations in Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements about the company's business resilience and the impact of weakened customer spending, as well as failing to disclose the negative effects of updated milestone criteria on the Regenerative Medicine Program revenue [8].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during the specified class period [1][2]. Summary by Sections Allegations - The complaint alleges that 3D Systems Corporation understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [1]. - It is also claimed that updated milestone criteria in the partnership with United Therapeutics Corporation would negatively affect the revenue from the company's regenerative medicine program [1]. - As a result, the company's public statements were materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the lawsuit is from August 13, 2024, to May 12, 2025 [1]. - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses due to misleading statements or omissions [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward before the August 12, 2025 deadline for lead plaintiff applications in a federal securities class action [2][4]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, reflecting a 3.4% year-over-year decline [5]. - For the full year 2024, the company reported sales of $440.1 million, a decrease of 10% compared to the previous year, attributed to lower hardware systems sales due to macroeconomic factors [5]. - In Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, and a net loss of $37 million, or $0.28 per share, more than doubling the loss from Q1 2024 [6]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [5]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [7]. Allegations and Legal Context - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding the impact of weakened customer spending and the revenue from its Regenerative Medicine Program [4]. - The firm is encouraging anyone with information regarding 3D Systems' conduct to contact them, including whistleblowers and former employees [8].